REAL WORLD EVIDENCE OF THE RISK OF A SECOND CANCER AMONG TESTICULAR CANCER PATIENTS AFTER CISPLATIN-BASED TREATMENT

被引：0
|
作者：
Luciano, S. [1 ]
Fazio-Eynullayeva, E. [2 ]
Kuranz, S. [1 ]
Stetson, B. [1 ]
机构：
[1] TriNetX Inc, Cambridge, MA USA
[2] TriNetX Inc, Revere, MA USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN183
引用
收藏
页码：S55 / S55
页数：1
相关论文
共 50 条
  • [21] TESTICULAR FUNCTION IN PATIENTS WITH TESTICULAR CANCER TREATED WITH ORCHIECTOMY ALONE OR ORCHIECTOMY PLUS CISPLATIN-BASED CHEMOTHERAPY
    HANSEN, PV
    TRYKKER, H
    HELKJAER, PE
    ANDERSEN, J
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1989, 81 (16) : 1246 - 1250
  • [22] Vascular fingerprint tool to identify testicular cancer patients at high-risk for early cardiovascular events after cisplatin-based chemotherapy
    Meuleman, A. T.
    Volders, E.
    Lubberts, S.
    Kerst, J. M.
    Wymenga, M.
    Aarts, M. J. B.
    Goncalves, M. Brito
    Lefrandt, J.
    Steursma, G.
    Meijer, C.
    Nuver, J.
    Gietema, J. A.
    ANNALS OF ONCOLOGY, 2023, 34 : S505 - S506
  • [23] Paternity and Testicular Function Among Testicular Cancer Survivors Treated With Two to Four Cycles of Cisplatin-Based Chemotherapy
    Brydoy, Marianne
    Fossa, Sophie D.
    Klepp, Olbjorn
    Bremnes, Roy M.
    Wist, Erik A.
    Wentzel-Larsen, Tore
    Dahl, Olav
    EUROPEAN UROLOGY, 2010, 58 (01) : 134 - 140
  • [24] ACUTE SUBJECTIVE MORBIDITY AFTER CISPLATIN-BASED COMBINATION CHEMOTHERAPY IN PATIENTS WITH TESTICULAR CANCER - A PROSPECTIVE-STUDY
    AASS, N
    FOSSA, SD
    OTTO, F
    OSE, T
    RADIOTHERAPY AND ONCOLOGY, 1989, 14 (01) : 27 - 33
  • [25] Adverse Health Outcomes Among US Testicular Cancer Survivors After Cisplatin-Based Chemotherapy vs Surgical Management
    Agrawal, Vaibhav
    Dinh, Paul C., Jr.
    Fung, Chunkit
    Monahan, Patrick O.
    Althouse, Sandra K.
    Norton, Kelli
    Cary, Clint
    Einhorn, Lawrence
    Fossa, Sophie D.
    Adra, Nabil
    Travis, Lois B.
    JNCI CANCER SPECTRUM, 2020, 4 (02)
  • [26] First salvage treatment in patients with advanced germ cell cancer after cisplatin-based chemotherapy: analysis of a registry of the German Testicular Cancer Study Group (GTCSG)
    Berger, Lars Arne
    Bokemeyer, Carsten
    Lorch, Anja
    Hentrich, Marcus
    Kopp, Hans-Georg
    Gauler, Thomas Christoph
    Beyer, Joerg
    de Wit, Maike
    Mayer, Frank
    Boehlke, Ina
    Oing, Christoph
    Honecker, Friedemann
    Oechsle, Karin
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2014, 140 (07) : 1211 - 1220
  • [27] Treatment of Patients With Metastatic Urothelial Cancer "Unfit" for Cisplatin-Based Chemotherapy
    Galsky, Matthew D.
    Hahn, Noah M.
    Rosenberg, Jonathan
    Sonpavde, Guru
    Hutson, Thomas
    Oh, William K.
    Dreicer, Robert
    Vogelzang, Nicholas
    Sternberg, Cora N.
    Bajorin, Dean F.
    Bellmunt, Joaquim
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (17) : 2432 - 2438
  • [28] First salvage treatment in patients with advanced germ cell cancer after cisplatin-based chemotherapy: analysis of a registry of the German Testicular Cancer Study Group (GTCSG)
    Lars Arne Berger
    Carsten Bokemeyer
    Anja Lorch
    Marcus Hentrich
    Hans-Georg Kopp
    Thomas Christoph Gauler
    Jörg Beyer
    Maike de Wit
    Frank Mayer
    Ina Boehlke
    Christoph Oing
    Friedemann Honecker
    Karin Oechsle
    Journal of Cancer Research and Clinical Oncology, 2014, 140 : 1211 - 1220
  • [29] Increased risk of non-germ cell second cancer (SC) after cisplatin-based chemotherapy (CBCT) in 1-year testicular cancer (TC) survivors (TCS)
    Hellesnes, R.
    Kvammen, O.
    Bremnes, R. M.
    Karlsdottir, A.
    Myklebust, T. A.
    Negaard, H.
    Tandstad, T.
    Wilsgaard, T.
    Fossa, S. D.
    Haugnes, H. S.
    ANNALS OF ONCOLOGY, 2018, 29 : 324 - 324
  • [30] Real-world outcomes of 5-FU-based second-line therapy in patients with advanced biliary tract cancer refractory to gemcitabine and cisplatin-based treatment
    Park, S. J.
    Kim, I-H.
    Shin, K.
    Cho, D.
    Lee, K.
    ANNALS OF ONCOLOGY, 2024, 35 : S130 - S130
12345